OBJECTIVE: To compare the efficacy and safety of amphotericin B and voriconazole induction therapy combined with itraconazole consolidation therapy in the treatment of acquired immune deficiency syndrome（AIDS） patients with talaromycosis marneffei（TSM）. METHODS: A total of 180 AIDS patients with TSM admitted into the hospital from Dec. 2018 to Mar. 2021 were extracted to be divided into the amphotericin B group and voriconazole group via the random number table method

with 90 patients in each group. Amphotericin B group was treated with amphotericin B induction therapy combined with itraconazole consolidation therapy

while voriconazole group received voriconazole induction therapy combined with itraconazole consolidation therapy. The clinical efficacy

blood routine

liver and kidney functions of two groups were observed. RESULTS: The total clinical effective rate of amphotericin B group was 94.44%（85/90）

and that of voriconazole group was 93.33%（84/90）

the difference was not statistically significant（P>0.05）. There was no significant difference in the levels of white blood cell count

platelet count

hemoglobin

aspartate aminotransferase and alanine aminotransferase between two groups before and after treatment（P>0.05）. Before treatment

there was no significant difference in serum levels of creatinine and cystatin C between two groups（P>0.05）; after treatment

the serum levels of creatinine and cystatin C in the amphotericin B group were significantly higher than those of the voriconazole group

the difference was statistically significant（P<0.05）. CONCLUSIONS: The effectiveness and liver function damage of amphotericin B and voriconazole induction therapy combined with itraconazole consolidation therapy for AIDS patients with TSM are comparable

yet voriconazole causes less liver function damage in patients.